COVID-19 SARS-CoV-2 preprints from medRxiv and bioRxiv

31,047 Articles (22,627 medRxiv, 8,420 bioRxiv)

Most recent first Previous |  Page 602: Articles 6011-6020  | Next

A pan-variant mRNA-LNP T cell vaccine protects HLA transgenic mice from mortality after infection with SARS-CoV-2 Beta
Carter, B., Huang, P., Liu, G., Liang, Y., Lin, P. J. C., Peng, B.-H., McKay, L., Dimitrakakis, A., Hsu, J., Tat, V., Saenkham-Huntsinger, P., Chen, J., Kaseke, C., Gaiha, G. D., Xu, Q., Griffiths, A., Tam, Y. K., Tseng, C.-T. K., Gifford, D. K.
10.1101/2022.09.23.509206 — Posted: 2022-09-26
PF-D-Trimer, a broadly protective SARS-CoV-2 subunit vaccine: immunogenicity and application
Zhang, Z., Zhou, J., Ni, P., Hu, B., Deng, S., Xiao, Q., He, Q., Li, G., Xia, Y., Liu, M., Wang, C., Fang, Z., Xia, N., Zhang, Z.-R., Zhang, B., Cai, K., Jolicoeur, N., Xu, Y., Liu, B.
10.1101/2022.09.26.509414 — Posted: 2022-09-26
Post COVID-19 condition after Wildtype, Delta, and Omicron variant SARS-CoV-2 infection and vaccination: pooled analysis of two population-based cohorts
Ballouz, T., Menges, D., Kaufmann, M., Amati, R., Frei, A., von Wyl, V., Fehr, J. S., Albanese, E., Puhan, M. A.
10.1101/2022.09.25.22280333 — Posted: 2022-09-26
Protection of homologous and heterologous boosters after primary schemes of rAd26-rAd5, ChAdOx1 nCoV-19 and BBIBP-CorV during the Omicron outbreak in adults of 50 years and older in Argentina: a test-negative case-control study.
Gonzalez, S., Olszevicki, S., Gaiano, A., Salazar, M., Regairaz, L., Varela Baino, A. N., Bartel, E., Varela, T., Gonzalez Martinez, V., Pesci, S., Marin, L., Irassar, J. I., Ceriani, L., Garcia, E., Kreplak, N., Estenssoro, E., Marsico, F.
10.1101/2022.09.25.22280341 — Posted: 2022-09-26
Impact of cross-coronavirus immunity in post-acute sequelae of COVID-19
Herman, J. D., Atyeo, C., Zur, Y., Cook, C. E., Patel, N. J., Vanni, K. M., Kowalski, E. N., Qian, G., Shadick, N. A., Lauffenburger, D. A., Wallace, Z. S., Sparks, J. A., Alter, G.
10.1101/2022.09.25.22280335 — Posted: 2022-09-26
Markers of blood-brain barrier disruption increase early and persistently in COVID-19 patients with neurological manifestations
Bonetto, V., Pasetto, L., Lisi, I., Carbonara, M., Zangari, R., Ferrari, E., Punzi, V., Luotti, S., Bottino, N., Biagianti, B., Moglia, C., Fuda, G., Gualtierotti, R., Blasi, F., Canetta, C., Montano, N., Tettamanti, M., Camera, G., Grimoldi, M., Negro, G., Rifino, N., Calvo, A., Brambilla, P., Biroli, F., Bandera, A., Nobili, A., Stocchetti, N., Sessa, M., Zanier, E.
10.1101/2022.09.26.22280358 — Posted: 2022-09-26
Impact of COVID-19 pandemic on the incidence of suicidal behaviors: a retrospective analysis of integrated electronic health records in a 7.5-million population
Valero-Bover, D., Fradera, M., Carot-Sans, G., Parra, I., Piera-Jimenez, J., Pontes, C., Palao-Vidal, D.
10.1101/2022.09.26.22280233 — Posted: 2022-09-26
Impact of the COVID-19 restrictions on the epidemiology of Cryptosporidium spp. in England and Wales, 2015-2021A time-series analysis
Adamson, J., Chalmers, R., Thomas, D. R., Elwin, K., Robinson, G., Barrasa, A.
10.1101/2022.09.26.22280357 — Posted: 2022-09-26
Inhibition of Phosphodiesterase 12 results in Antiviral Activity against several RNA Viruses including SARS-CoV-2.
Karayiannis, P., Thursz, M., Sadiq, F., Tree, J., Beasley, D., Dejnirattisai, W., Mongkolsapaya, J., Screaton, G., Wand, M., Elmore, M., Miles, C., Matthews, I., Thomas, H.
10.1101/2022.09.23.509178 — Posted: 2022-09-26
Post-Concussion Assessment as a diagnostic and mechanistic framework for treating patients with Long COVID
Davidson, B., Noteboom, L., Pierro, H., Kantor, C., Stoot, D., Stoot, F., Linseman, D., Hale, T., Gorgens, K.
10.1101/2022.09.24.22280310 — Posted: 2022-09-25

RSS  Collection RSS | JSON

The feeds linked above output metadata for the 100 most recent papers in the collection.To access the metadata for the entire collection in JSON or XML, visit the collection API.

Subject Areas
* The Clinical Trials and Epidemiology subject categories are now closed to new submissions following the completion of bioRxiv's clinical research pilot project and launch of the dedicated health sciences server medRxiv (submit.medrxiv.org). New papers that report results of Clinical Trials must now be submitted to medRxiv. Most new Epidemiology papers also should be submitted to medRxiv, but if a paper contains no health-related information, authors may choose to submit it to another bioRxiv subject category (e.g., Genetics or Microbiology).